BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, announced additional funding in the amount of $2.9 million through convertible promissory notes. The company also announced the addition of Lawrence Blake Jones to its board of directors.
